Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H2, 2017

2017-08-30
Price :
Published : Aug-2017
No. of Pages : 80

Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H2, 2017

Summary

GlobalData’s clinical trial report, “Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H2, 2017” provides an overview of Genital Warts (Condylomata Acuminata) clinical trials scenario. This report provides top line data relating to the clinical trials on Genital Warts (Condylomata Acuminata). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Neurocrine Biosciences Inc (NBIX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Neurocrine Biosciences Inc (Neurocrine) discovers, develops and commercializes pharmaceutical products for the treatment of neurologic, psychiatric and endocrine related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule is a US FDA approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). Its other major pipeline products include elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis and uterine fibroids and opicapone, a catechol-O-methyltransferase inhibitor (COMT inhibitor) intended for adult patients with Parkinson's disease. It also develops drug candidates for the treatment of essential tremor and classic congenital adrenal hyperplasia. The company ha......
$250

Exelixis Inc (EXEL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Exelixis Inc (Exelixis) is a biopharmaceutical company focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has three product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma; and Cotellic (cobimetinib) is developed in combination with vemurafenib for the treatment of patients with mutation-positive advanced melanoma. The company also enters into collaborative partnerships with pharmaceutical and biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in South San Francisco, California, the US......
$250

Express Scripts Holding Co (ESRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Express Scripts Holding Company (Express Scripts) is a pharmacy benefit management (PBM) company. It provides integrated pharmacy-benefit management services such as home delivery pharmacy services, specialty benefit management, network-pharmacy claims processing, formulary management, and medical and drug data analysis services. It also distributes a wide range of biopharmaceutical products and prescription drugs for specialty and orphan diseases; and provides cost-management and patient-care services. Express Scripts caters its services to clinics, managed care organizations, providers, hospitals, employers, union-sponsored benefit plans, health insurers, third-party administrators, workers' compensation plans and government health programs. Express Scripts is headquartered in S......
$250

Chugai Pharmaceutical Co Ltd (4519) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Chugai Pharmaceutical Co Ltd (Chugai), a subsidiary of Hoffmann-La Roche Ltd, is a provider of biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of cancer; bone and joint diseases; renal diseases; immunology and infectious diseases and others. It also offers drugs to aid kidney, liver and other organ transplantations. Chugai's major products include Avastin (bevacizumab), Herceptin (trastuzumab), Rituxan (rituximab), Actemra (tocilizumab), Edirol (eldecalcitol) and Mircera (epoetin beta pegol). It also has a range of product candidates in its pipeline. The company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co Ltd (4519) - ......
$250

BASF SE (BAS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary BASF SE (BASF) is a chemical company, which carries out research and development (R&D), production, marketing and sales of chemicals, plastics, crop protection products, and performance products. Its product line comprises solvents, adhesives, surfactant, organic chemicals, fuel additives, electronic chemicals, concrete admixtures, pigments, paints, food additives, fungicides, and herbicides. BASF also focuses on exploration and production in oil and gas-rich regions in Europe, North Africa, Russia, South America and the Middle East. The company caters to a wide range of industries including construction, furniture and wood, agriculture, paper and pulp, electronics and electrical, paints and coatings, automotive, home care, nutrition, chemicals and others. BASF carries out R&D in ......
$250

DaVita Inc (DVA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary DaVita Inc (DaVita), formerly DaVita HealthCare Partners Inc., is a provider of dialysis services and integrated health care delivery and management services. The company is a provider of dialysis services in the US for patients with chronic kidney failure and end-stage renal disease (ESRD). It also focuses on providing integrated health care delivery and management services. It also offers ancillary services, including pharmacy services such as DaVita Rx; infusion therapy services, disease management services; vascular access services; ESRD clinical research programs and physician services. The company operates through a network of outpatient dialysis centers in hospitals and related laboratory services. DaVita Medical Group manages and operates medical groups and affiliated phys......
$250

Heidelberg Pharma AG (WL6) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Heidelberg Pharma AG(Heidelberg Pharma) formerly known as Wilex AG is a biopharmaceutical company with a focus on cancer. The company develops therapeutic and diagnostic product candidates for the treatment and specific detection of various cancers. It develops products based on and small molecules and antibodies, which are offered for out-licensing. Wilex's pipeline products are focused at treating multiple myeloma, prostate cancer, hematological cancers, metastatic pancreatic cancers, leukemia, non- metastatic ccRCC, kidney cancers and solid tumors. Heidelberg Pharma GmbH (Heidelberg), Wilex's subsidiary provides preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Heidelberg focuses on the development of a proprietary ADC technology. ......
$250

Taiho Pharmaceutical Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Taiho Pharmaceutical Co Ltd (Taiho), a subsidiary of Otsuka Group focuses on the development, production and marketing of pharmaceutical products in the fields of cancer, allergy, immunology, urology and others. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor antagonists, antibiotics and medical devices; and consumer health products such as vitamin tonic, herbal digestive medicine, topical analgesics, antifungal cream, herbal medicine powder, and others. Taiho has production facilities in Tokushima, Saitama, Okayama, Kitajima and Inuyama. It operates through its subsidiaries in Japan, China, Singapore, the UK and the US. Taiho is headquartered in Tokyo, Japan. Taiho Pharmaceutical Co Ltd - Pharmaceuticals & Healt......
$250

Evotec AG (EVT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Evotec AG (Evotec) is a drug discovery alliance and development partnership company. It identifies and develops small molecule drugs across various therapeutic areas such as, cancer, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory diseases. Evotec provides services such as integrated services, assay development and screening, reagent production services, ADMET, cellular target profiling, vitro pharmacology services and proteomics services. The company has long-term discovery alliances with several leading pharmaceutical companies and also has development partnerships for product candidates in clinical and pre-clinical development stages. The company has operating facilities in Abingdon and Manchester, the UK; Gottingen and M......
$250

Weifa ASA (WEIFA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Weifa ASA (Weifa), formerly Aqualis ASA, is a pharmaceutical company that conducts the research and development, manufacture, distribution and sales of pharmaceutical products, lifestyle products and solutions. The company has over the counter (OTC) pharmaceutical market in Norway offering products for pain relief; treatment of cough and colds; dermatology; Nutraceuticals; dietary supplements; and wound treatment among others. Its research and development activities focus on prescription drug products, OTC products and nutraceuticals. It offers products to consumers, customers and professional partners. The company has operational presence in Denmark, Iceland, Sweden and Finland. Weifa is headquartered in Oslo, Norway. Weifa ASA (WEIFA) - Pharmaceuticals & Healthcare - Deals and ......
$250